PDS Biotechnology Announces Conference Call and Webcast for Second Quarter 2020 Financial Results
PDS Biotechnology Corporation (PDSB) will announce its second-quarter financial results for the period ending June 30, 2020, on August 13, 2020, before market opening. Following the announcement, executives including Dr. Frank Bedu-Addo will host a conference call to discuss the results and provide a business update at 8:00 am ET. Interested parties can join via phone or through a live webcast on PDS Biotech’s investor relations page. The event will be archived for six months for further access.
- Scheduled financial results announcement for Q2 2020 shows commitment to transparency.
- Conference call will provide insights into business updates, which may interest investors.
- None.
FLORHAM PARK, N.J., July 30, 2020 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune® T-cell activating technology, today announced that the Company will report financial results for the second quarter ended June 30, 2020 on Thursday, August 13, 2020, before the market opens. Following the release, Dr. Frank Bedu-Addo, Chief Executive Officer, Michael King, Interim Chief Financial Officer, and Dr. Lauren Wood, Chief Medical Officer will host a conference call to review the financial results and provide a business update.
The conference call is scheduled to begin at 8:00 am ET on Thursday, August 13, 2020. Participants should dial 877-407-3088 (United States) or 201-389-0927 (International) and mention PDS Biotechnology. A live webcast of the conference call will also be available on the investor relations page of the Company's corporate website at www.pdsbiotech.com.
After the live webcast, the event will be archived on PDS Biotech’s website for 6 months. In addition, a telephonic replay of the call will be available for 6 months. The replay can be accessed by dialing 877-660-6853 (United States) or 201-612-7415 (International) with confirmation code 13707451.
About PDS Biotechnology
PDS Biotech is a clinical-stage immunotherapy company with a growing pipeline of cancer immunotherapies and infectious disease vaccines based on the Company’s proprietary Versamune® T-cell activating technology platform. Versamune® effectively delivers disease-specific antigens for in vivo uptake and processing, while also activating the critical type 1 interferon immunological pathway, resulting in production of potent disease-specific killer T-cells as well as neutralizing antibodies. PDS Biotech has engineered multiple therapies, based on combinations of Versamune® and disease-specific antigens, designed to train the immune system to better recognize disease cells and effectively attack and destroy them. To learn more, please visit www.pdsbiotech.com or follow us on Twitter at @PDSBiotech.
Media & Investor Relations Contact:
Deanne Randolph
PDS Biotech
Phone: +1 (908) 517-3613
Email: drandolph@pdsbiotech.com
Alexander Lobo
The Ruth Group
Phone: +1 (646) 536-7037
Email: alobo@theruthgroup.com
FAQ
When will PDS Biotechnology report its Q2 2020 financial results?
What time is the conference call for PDS Biotechnology's financial results?
How can I access the PDS Biotechnology financial results conference call?
What is the focus of PDS Biotechnology's business?
